NCT05999032 The Puerto Rico Asthma Integrated Response Program ("PR-AIR")
| NCT ID | NCT05999032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rhode Island Hospital |
| Condition | Pediatric Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 480 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 480 participants in total. It began in 2024-12-16 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to adapt and deliver an evidence-based multi-level intervention to reduce asthma disparities, and that promote and improve population health in the high-burden communities of San Juan, Puerto Rico. The Puerto Rico-Asthma Integrated Response Program (PR-AIR) will be implemented and evaluated to address pediatric asthma disparities in San Juan, PR, an area of high asthma burden. This study unfolds in two phases: In Phase 1, the researchers will collaborate with community stakeholders to identify needs, barriers and facilitators of PR-AIR implementation. Phase 2 consists of an evaluation of low-intensity (virtual) and high-intensity (in-person) methods of PR-AIR implementation outcomes using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework and a mixed methods approach.
Eligibility Criteria
Inclusion Criteria: 1. Children between the ages of 2 and 12 years old 2. Children must reside in one of the identified catchment areas 3. Children must meet the screening criteria as having not well controlled or poorly controlled asthma Exclusion Criteria: 1\. Children with complex medical conditions
Contact & Investigator
Daphne Koinis Mitchell, PhD
PRINCIPAL INVESTIGATOR
Rhode Island Hospital
Frequently Asked Questions
Who can join the NCT05999032 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 12 Years, studying Pediatric Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05999032 currently recruiting?
Yes, NCT05999032 is actively recruiting participants. Contact the research team at dkoinismitchell@lifespan.org for enrollment information.
Where is the NCT05999032 trial being conducted?
This trial is being conducted at Providence, United States, San Juan, Puerto Rico.
Who is sponsoring the NCT05999032 clinical trial?
NCT05999032 is sponsored by Rhode Island Hospital. The principal investigator is Daphne Koinis Mitchell, PhD at Rhode Island Hospital. The trial plans to enroll 480 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.